Videos

An overview of the remarkable evolution in the treatment landscape for metastatic and recurrent cervical cancer patients, shaped by pivotal clinical trials and the integration of immunotherapy, resulting in significantly improved clinical outcomes.

A key opinion leader explores the significance of biomarkers, including PD-L1 CPS score, TMB, MSI, and HER2, in shaping advanced treatment strategies for cervical cancer patients, emphasizing personalized care and clinical trial opportunities.

Expert insight into the pivotal role of HPV vaccines, evolving vaccination strategies, and advanced screening methods in cervical cancer prevention and management on a global scale.

Ramez N. Eskander, MD, discusses a challenging cervical cancer case, highlighting treatment advances and decision-making in recurrent and metastatic settings.

Robert J. Motzer, MD, concludes the program with insights on promising treatment options for patients with non–clear cell renal cell carcinoma.

Expert Matthew Lunning, DO, FACP, shares his excitement for an upcoming case-based peer perspectives program wherein he reviews the diagnosis and management of a patient with DLBCL, considering evolving treatment paradigms and updated clinical data.

Madhav V. Dhodapkar, MBBS, discusses some of the immunotherapies under investigation and those that are being highlighted at the 20th International Myeloma Society Annual Meeting for patients with multiple myeloma.

Expert oncologist Sandip Patel, MD, discusses treatment decisions for a 62-year-old female with squamous cell lung cancer, highlighting the use of CTLA4 and PD1 inhibitors based on subgroup analysis.

Jamie L. Koprivnikar, MD, closes by sharing some future insights and remaining unmet needs for patients with myelodysplastic syndrome.

Expert oncologist Anne Tsao, MD, shares her excitement for an upcoming precision medicine program focused on the evolving role of TROP2-directed antibody drug conjugates in metastatic non-small cell lung cancer.

Dr Jamie L. Koprivnikar discusses the rationale surrounding luspatercept as a potential first-line treatment option for patients with myelodysplastic syndrome, and if it would have been an appropriate therapy for the patient in the presented case study.

Rebecca A. Shatsky, MD, provides an overview of ER+/HER2- metastatic breast cancer and discusses its incidence and prevalence.

Dr Ajai Chari highlights the advantages of approved bispecific therapies as off-the-shelf options for patients with rapidly progressing multiple myeloma, highlighting the necessity for Phase 3 studies to confirm long-term benefits and safety. In closing, Dr Chari emphasizes the role of healthcare teams in managing side effects and complications, supporting the utility of bispecifics through unprecedented remissions and improved quality of life for patients.

Ajai Chari, MD, discusses managing toxicities in patients with relapsed/refractory multiple myeloma treated with emerging bispecific therapies, emphasizing common adverse events including cytokine release syndrome, target-related toxicities such as neutropenia, and mitigation strategies such as pre-medication, early intervention with tocilizumab, and dose modulation.

Daniel P. Petrylak, MD, discusses background and findings from the phase 3 KEYNOTE-921 study of pembrolizumab plus docetaxel vs placebo plus docetaxel in patients with metastatic castration-resistant prostate cancer who had received prior next-generation hormonal agent therapy.

Dr Ajai Chari highlights the CARTITUDE-1 study for its impressive results in the treatment of patients with relapsed/refractory multiple myeloma, noting a high response rate after three-year updates, which led to the accelerated approval of cilta-cel therapy.

Ajai Chari, MD, details the accelerated FDA approval of talquetamab based on data from the MonumenTAL-1 study showing positive response rates in patients with advanced multiple myeloma. The study highlighted the latest efficacy results of every-two-week dosing, which demonstrated an advantageous option for patients treated with four or more lines of therapy and triple class exposure.

Dr Ajai Chari discusses the various treatments available for patients with relapsed/refractory multiple myeloma and emphasizes the paradigm-changing impact of emerging therapies.

Ajai Chari, MD, presents the case of a 71-year-old woman with relapsed/refractory multiple myeloma who showed signs of disease progression after four lines of therapy and was initiated on a recently FDA-approved bispecific antibody, talquetamab.

Joshua Richter, MD, evaluates the efficacy and safety data of linvoseltamab for the treatment of patients with multiple myeloma.

Cyrus M. Khan, MD, discusses the phase 1/2 trial of glofitamab for use as a treatment option for patients with relapsed/refractory large B-cell lymphoma.

UCLA professor, Richard S. Finn, MD, discusses the next possible regimen for hepatocellular carcinoma.

John Lister, MD, discusses the current role of stem cell transplant in the treatment of T-cell lymphoma, and some of the latest advances in the space.

Chung-Han Lee, MD, PhD, discusses the types of research that are needed to push forward the development of adjuvant treatments for patients with renal cell carcinoma.

Samer A. Srour, MB, ChB, MS, discusses the design of ALLO-316, an agent investigated in the phase 2 TRAVERSE trial for patients with renal cell carcinoma.

Binod Dhakal, MD, MS, provides background on the phase 3 CARTITUDE-4 study of ciltacabtagene autoleucel for the treatment of patients with lenalidomide-refractory multiple myeloma.

Amer Zeidan, MBBS, discusses the rationale of studying imetelstat in the phase 3 IMerge trial in patients with lower-risk myelodysplastic syndrome.

A review of the rationale and study design of the phase 3 COMMANDS trial and subsequent subgroup analysis data recently presented at the ASCO and EHA 2023 Annual Meetings.

A medical oncologist reviews recent data updates from the 2023 ASCO Annual Meeting for non–clear cell renal cell carcinoma.

Clinical insights from a leader in kidney cancer research on the differences between clear cell and non–clear cell renal cell carcinoma.